Gastric subtype of intraductal papillary neoplasm of the bile duct: The pathologic spectrum.


Journal

Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 29 10 2019
revised: 14 04 2020
accepted: 20 04 2020
pubmed: 2 5 2020
medline: 17 7 2021
entrez: 2 5 2020
Statut: ppublish

Résumé

Intraductal papillary neoplasms of bile duct (IPNBs) remain a challenging entity to manage. The pathologic spectrum of 34 gastric subtype of IPNB (gIPNB) cases was examined in consideration of the type 1 and 2 subclassification proposed by Japan-Korea consensus and compared with gastric subtype of pancreatic intraductal papillary mucinous neoplasm (gIPMN) (44 cases). Type 1 gIPNBs (17 cases) showed regular papillary foveola with variable tubular pyloric glands. Eight of the type 1 gIPNBs showed low-grade dysplasia. Type 2 cases (n = 17) showed complicated papillary and tubular structures and high-grade dysplastic foveola and pyloric glands. Foveolas were predominant in 15 cases, while pyloric glands were predominant in 10 cases, and considerable areas of foveolas and pyloric glands in the remaining: these three were found similarly in type 1 and 2 gIPNB. gIPMNs showed central foveola with a peripheral pyloric gland. Such a pattern was recognizable in type 1 but vague in type 2. Type 1 was frequently found in the intrahepatic bile ducts and showed abundant mucin, as in gIPMNs, while type 2 also occurred in the extrahepatic bile ducts and were pathologically more malignant. Type 1 lesions shared features of gIPMN, while type 2 lesions differed from gIPMN and were more pathologically malignant.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Intraductal papillary neoplasms of bile duct (IPNBs) remain a challenging entity to manage.
METHODS METHODS
The pathologic spectrum of 34 gastric subtype of IPNB (gIPNB) cases was examined in consideration of the type 1 and 2 subclassification proposed by Japan-Korea consensus and compared with gastric subtype of pancreatic intraductal papillary mucinous neoplasm (gIPMN) (44 cases).
RESULTS RESULTS
Type 1 gIPNBs (17 cases) showed regular papillary foveola with variable tubular pyloric glands. Eight of the type 1 gIPNBs showed low-grade dysplasia. Type 2 cases (n = 17) showed complicated papillary and tubular structures and high-grade dysplastic foveola and pyloric glands. Foveolas were predominant in 15 cases, while pyloric glands were predominant in 10 cases, and considerable areas of foveolas and pyloric glands in the remaining: these three were found similarly in type 1 and 2 gIPNB. gIPMNs showed central foveola with a peripheral pyloric gland. Such a pattern was recognizable in type 1 but vague in type 2. Type 1 was frequently found in the intrahepatic bile ducts and showed abundant mucin, as in gIPMNs, while type 2 also occurred in the extrahepatic bile ducts and were pathologically more malignant.
CONCLUSION CONCLUSIONS
Type 1 lesions shared features of gIPMN, while type 2 lesions differed from gIPMN and were more pathologically malignant.

Identifiants

pubmed: 32356328
doi: 10.1002/jhbp.751
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

402-413

Informations de copyright

© 2020 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Références

Nakanuma Y, Basturk O, Esposito I, Klimstra DS, Komuta M, Zen Y. Intraductal papillary neoplasm of the bile duct. In: The WHO classification of tumor editorial board, editor. WHO Classification of Tumors. Digestive System Tumours, 5 ed. Lyon, France: International Agency for Research on Cancer, 2019; p. 279-82.
Chen TC, Nakanuma Y, Zen Y, Chen MF, Jan YY, Yeh TS, et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology. 2001;34:651-8.
Nakanuma Y, Kakuda Y, Uesaka K, Miyata T, Yamamoto Y, Fukumura Y, et al. Characterization of intraductal papillary neoplasm of bile duct with respect to histopathologic similarities to pancreatic intraductal papillary mucinous neoplasm. Hum Pathol. 2016;51:103-13.
Nitta T, Nakanuma Y, Sato Y, Hirano S, Pairojkul C. Pathological characteristics of intraductal polypoid neoplasms of bile ducts in Thailand. Int J Clin Exp Pathol. 2015;8:8284-90.
Park HJ, Kim SY, Kim HJ, Lee SS, Hong GS, Byun JH, et al. Intraductal papillary neoplasm of the bile duct: clinical, imaging, and pathologic features. AJR Am J Roentgenol. 2018;211:67-75.
Rocha FG, Lee H, Katabi N, DeMatteo RP, Fong Y, D'Angelica MI, et al. Intraductal papillary neoplasm of the bile duct: A biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology. 2012;56:1352-60.
Yang CY, Huang WJ, Tsai JH, Cheng A, Chen CC, Hsu HP, et al. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct. Mod Pathol. 2019;32:1637-45.
Fujikura K, Akita M, Ajiki T, Fukumoto T, Itoh T, Zen Y. Recurrent mutations in APC and CTNNB1 and activated Wnt/β-catenin signaling in intraductal papillary neoplasms of the bile duct: a whole exome sequencing study. Am J Surg Pathol. 2018;42:1674-85.
Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, et al. Similarities and differences between intraductal papillary tumors of the bile duct with and without macroscopically visible mucin secretion. Am J Surg Pathol. 2011;35:512-21.
Nakanuma Y, Kakuda Y, Fukumura Y, Sugino T, Uesaka K, Serizawa M, et al. The pathologic and genetic characteristics of the intestinal subtype of intraductal papillary neoplasms of the bile duct. Am J Surg Pathol. 2019;43:1212-20.
Albores-Saavedra J, Murakata L, Krueger JE, Henson DE. Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts. Cancer. 2000;89:508-15.
Fujikura K, Fukumoto T, Ajiki T, Otani K, Kanzawa M, Akita M, et al. Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas. Histopathology. 2016;69:950-61.
Basturk O, Esposito I, Fukushima N, Fukukawa T, Hong SM, Kloppel G, et al. Pancreatic intraductal papillary mucinous neoplasm. In: The WHO classification of tumor editorial board, editor. WHO Classification of Tumors, Digestive System Tumours, 5 ed. Lyon, France: International Agency for Research on Cancer, 2019; p. 310-4.
Basturk O, Esposito I, Fukushima N, Fukukawa T, Hong SM, Kloppel G, et al. Pancreatic intraductal oncocytic neoplasm. In: The WHO classification of tumor editorial board, editor. WHO Classification of Tumors, Digestive System Tumours, 5 ed. Lyon, France: International Agency for Research on Cancer, 2019; p. 315-6.
Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, Shiratori K, et al. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant. J Pathol. 2013;231:335-41.
Wang T, Askan G, Allen P, Jarnagin WR, Memis B, Sigel C, et al. Intraductal oncocytic papillary neoplasms: clinical-pathologic characterization of 24 cases, with an emphasis on associated invasive carcinomas. Am J Surg Pathol. 2019;43:656-61.
Minagawa N, Sato N, Mori Y, Tamura T, Higure A, Yamaguchi K. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes. Eur J Surg Oncol. 2013;39:554-8.
Fukumura Y, Nakanuma Y, Kakuda Y, Takase M, Yao T. Clinicopathological features of intraductal papillary neoplasms of the bile duct: a comparison with intraductal papillary mucinous neoplasm of the pancreas with reference to subtypes. Virchows Arch. 2017;471:65-76.
Nakanuma Y, Kakuda Y, Uesaka K. Characterization of intraductal papillary neoplasm of the bile duct with respect to the histopathologic similarities to pancreatic intraductal papillary mucinous neoplasm. Gut and Liver. 2019;13:617-27.
Nakanuma Y, Uesaka K, Miyayama S, Yamaguchi H, Ohtsuka M. Intraductal neoplasms of the bile duct. A new challenge to biliary tract tumor pathology. Histol Histopathol. 2017;32:1001-15.
Nakanuma Y, Sudo Y. Biliary tumors with pancreatic counterparts. Semin Diagn Pathol. 2017;34:167-75.
Yamaguchi J, Mino-Kenudson M, Liss AS, Chowdhury S, Wang TC, Fernández-Del Castillo C, et al. Loss of trefoil factor 2 from pancreatic duct glands promotes formation of intraductal papillary mucinous neoplasms in mice. Gastroenterology. 2016;151:1232-44.
Nakanuma Y. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas? Pathol Int. 2010;60:419-29.
Nakanuma Y, Jang KT, Fukushima N, Furukawa T, Hong SM, Kim H, et al. A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage. J Hepatobiliary Pancreat Sci. 2018;25:181-7.
Schlitter AM, Jang KT, Klöppel G, Saka B, Hong SM, Choi H, et al. Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol. 2015;28:1249-64.
Lanzoni G, Cardinale V, Carpino G. The hepatic, biliary, and pancreatic network of stem/progenitor cell niches in humans: A new reference frame for disease and regeneration. Hepatology. 2016;64:277-86.
Hatzibougias DI, Fouzas I, Bobos M, Papanikolaou V, Daoudaki M, Kotoula V, et al. Tubular pyloric gland adenoma of the left and right hepatic ducts: report of a unique case with immunohistochemical and molecular studies. Int J Surg Pathol. 2016;2:347-52.
He C, Fukumura Y, Toriyama A, Ogura K, Sasahara N, Mitani K, et al. Pyloric gland adenoma (PGA) of the gallbladder: a unique and distinct tumor from PGAs of the stomach, duodenum, and pancreas. Am J Surg Pathol. 2018;42:1237-45.
Basturk O, Aishima S, Esposito I. Pyloric gland adenoma of the gallbladder. In: The WHO classification of tumor editorial board, editor. WHO Classification of Tumors, Digestive System Tumours, 5 ed. Lyon, France: International Agency for Research on Cancer, 2019; p. 271-2.

Auteurs

Yasuni Nakanuma (Y)

Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Department of Diagnostic Pathology, Fukui Prefecture Saiseikai Hospital, Fukui, Japan.

Katsuhiko Uesaka (K)

Department of Hepatobiliary Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.

Takuro Terada (T)

Departament of Hepatobiliary Pancreatic Surgery, Fukui Prefecture Saiseikai Hospital, Fukui, Japan.

Yukie Fukumura (Y)

Deparatment of Diagnostic Pathology, Juntendo School of Medicine, Tokyo, Japan.

Takashi Sugino (T)

Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan.

Yuko Kakuda (Y)

Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan.

Hiroko Ikeda (H)

Department of Diagnostic Pathology, Kanazawa University Hospital, Kanazawa, Japan.

Kenichi Harada (K)

Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.

Yasunori Sato (Y)

Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.

Shinichiro Shimizu (S)

Department of Diagnostic Pathology, Funahashi Central Hospital, Chiba, Japan.

Susumu Matsukuma (S)

Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa, Japan.

Jang Kee Taek (J)

Department of Diagnostic Pathology, Samsung Medical Center, Seoul, Korea.

Young Nyun Park (Y)

Department of Diagnostic Pathology, Yonsei University Medical Center, Seoul, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH